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Background: In 2009, the Global Fund to Fight AIDS, Tuberculosis and Malaria established the Affordable Medicines
Facility-malaria (AMFm) in order to increase access to quality-assured artemisinin combination therapy (QAACT).
AMFm Phase 1, which includes nine pilot programmes in eight countries, was launched in 2009. The objective of
this study was to assess anti-malarial stock and purchase patterns at private outlets in five AMFm Phase 1 countries
in regard to three of the core AMFm goals: increase the affordability of QAACT, increase the availability of QAACT,
and crowd out artemisinin monotherapies and other substandard therapies.
Methods: The study was conducted between April and May 2012 and included interviews with personnel in 598
private pharmaceutical outlets in Ghana, Kenya, Nigeria, Tanzania, and Uganda. Questionnaires were administered at
private retail outlets and the data were analyzed to assess within- and between-country differences in QAACT price,
availability, and popularity.
Results: AMFm medications were less expensive than their non-AMFm counterparts, yet prices for both types were
above country-specific suggested retail prices. Market penetration of AMFm QAACT in both urban and rural areas
was high, although stock-outs of both AMFm and non-AMFm products were more common in rural compared
with urban outlets in Ghana and Kenya (p = 0.0013). Government recommendation was the most significant factor
influencing anti-malarial stock choices in urban (41.5%) and rural (31.9%) outlets. The three top-selling anti-malarials
reported for both urban and rural areas in each country were, with the exception of rural Uganda and urban
Nigeria, combination therapies.
Conclusions: Results from this study indicate that the AMFm has not fully achieved its affordability and crowd-out
objectives. Still, the final purchase price of AMFm QAACT was substantially lower than non-AMFm equivalents.
Moreover, for both urban and rural areas, AMFm QAACT availability was found to be high, and the various forms of
QAACT were the best-selling products among all anti-malarials. These findings suggest a continued need for
initiatives like the AMFm that improve the affordability and accessibility of QAACT. Similar programmes may be
especially effective if employed in combination with rapid diagnostic testing to ensure the appropriate use of these
products.
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It is estimated that there were 216 million cases of mal-
aria and 655,000 malaria deaths in 2010. The majority of
cases (81%) and deaths (91%) occurred in the World
Health Organization (WHO) African region. In 2010,
there were 3.3 billion people at risk for malaria world-
wide, of whom 1.2 billion (47%) were considered at high
risk (> 1 case/1,000 population) and living in the WHO
African Region [1].
In 2006, the WHO recommended the first-line use of
artemisinin-based combination therapy (ACT) to address
the resistance of Plasmodium falciparum to monother-
apies and improve treatment outcomes [2]. Since 2000,
the use of ACT has helped reduce malaria-related deaths
in Europe by 99%, the Americas by 55%, and the Western
Pacific by 42%. During the same period, however, malaria
mortality in Africa was reduced by only 33% [1]. In 2010,
the WHO updated its malaria treatment guidelines to rec-
ommend that ACT replace oral artemisinin-based mono-
therapy [3]. As of November 2011, there were still 25
countries, primarily located in the Africa Region, which
continued to allow the marketing of artemisinin mono-
therapy [1].
The private sector plays a key role in the treatment of
malaria. A study of global malaria treatment found that up
to 60% of malaria medications are delivered in the private
sector [4]. There are several studies suggesting that achiev-
ing the Roll Back Malaria Partnership goal of providing
80% of malaria patients with effective treatment within
24 hours from symptom onset will depend on increasing
the availability of anti-malarial drugs outside the public
sector [5-7]. This finding is supported by an analysis of
six African countries, which found that the majority
of treatment-seeking febrile patients in the Democratic
Republic of Congo, Madagascar, Nigeria, and Uganda ini-
tially sought treatment in the private sector [8]. Addition-
ally, the private sector was the source of more than half of
the anti-malarials acquired for children under the age of
five with fever in these four countries [8].
In order to address the need for increased access to ACT
in both the private and public sector, the Global Fund to
Fight AIDS, Tuberculosis and Malaria established the
Affordable Medicines Facility-malaria (AMFm). This
programme negotiates reduced pricing with ACT manufac-
turers that provide quality-assured ACT (QAACT) by
agreeing to pay a significant co-payment, a strategy which
is intended to reduce the final purchase price of ACT for
patients. As defined by AMFm, QAACT is a formulation of
ACT that has been approved by the WHO Prequalification
Programme, which assures the safety, quality, and efficacy
of medicinal products [9]. The four core objectives of the
AMFm are to (1) increase the affordability of QAACT; (2)
increase the availability of QAACT; (3) increase the use of
QAACT; and (4) crowd out monotherapies and othersubstandard therapies [10]. Substandard therapies are those
that either do not ensure high cure rates of P. falciparum
malaria or increase the possibility of drug resistance. Sub-
standard therapies include artemisinin monotherapies and
products that contain inadequate or no artemisinin deriva-
tive [11,12].
In 2009, Phase 1 of the AMFm was launched with a $225
million commitment to support nine pilot programmes in
eight countries (Cambodia, Ghana, Kenya, Madagascar,
Niger, Nigeria, Tanzania, and Uganda). The Global Fund
has established pricing guidelines for manufacturers partici-
pating in the AMFm, indicating the maximum price that
manufacturers can offer to first-line buyers of ACT [13].
Countries participating in the AMFm may opt to set their
own suggested retail prices (SRPs). Initial SRPs for an
adult dose of ACT delivered to Phase 1 countries between
August 2010 and April 2011 ranged from US $0.42 to US
$1.00 [14].
An independent evaluation of the AMFm Phase 1 pilot
programmes, conducted in March 2012 based on survey
data collected between September 2009 and December
2010, found that AMFm QAACT was most widely available
in public health facilities in all countries except for Nigeria
and Madagascar [10]. Within all eight countries, the avail-
ability of QAACT in private outlets at baseline ranged from
6% in Niger to 27% in Nigeria. Non-artemisinin-based ther-
apy was more commonly available than QAACT in all
countries, and artemisinin monotherapy and low-quality
ACT were more frequently available than QAACT in sev-
eral countries [10].
Because patients receiving treatment in most public fa-
cilities and in many non-profit outlets do not pay for
QAACT, the median cost of an adult dose was zero in
public health facilities in all countries except for Ghana
and in private non-profit outlets in Kenya, Madagascar,
mainland Tanzania, and Uganda [10]. In private for-
profit outlets, the median price for an adult dose ranged
from $0.14 to $5.99. In private for-profit outlets, non-
artemisinin anti-malarials were the least expensive treat-
ments available in all countries, except Madagascar and
Uganda [10].
The objective of this study was to assess anti-malarial
stock and purchase patterns at private outlets in five
AMFm Phase 1 countries in regard to three of the core
AMFm goals: (1) increase the affordability of ACT; (2) in-
crease the availability of ACT; and (3) crowd out monother-
apies and other substandard therapies. All forms of ACT
systematically assessed in this study have been evaluated by
the WHO Prequalification of Medicines Programme.
Methods
Study population
Between April and May 2012, interviews were held in
598 private pharmaceutical outlets in five AMFm Phase
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Uganda). Information regarding outlets that are primary
recipients of AMFm products is available from several
sources, including Novartis International AG, the Global
Fund to Fight AIDS, Tuberculosis and Malaria, Popula-
tion Services International, and in-country distributors.
This information was compiled and compared to achieve
an extensive sampling frame of outlets in each country
that are primary recipients of AMFm products. From
this list, approximately 80 outlets per country were se-
lected using random sampling. In order to obtain a set
of outlets that were not primary recipients of AMFm
products, approximately 20 outlets per country not
appearing on the AMFm recipient list were selected by
convenience sampling. After examining geographic char-
acteristics of the 100 outlets selected per country, it was
determined that the majority were located in urban or
semi-urban areas. In order to better understand the im-
pact of AMFm in rural areas, an additional 20 rural out-
lets per country were selected. For the sampling of rural
outlets, two districts per country were chosen at random
from among all districts containing urban outlets that
are primary recipients of AMFm products. From each of
these districts, convenience and snowball sampling were
used to select ten rural outlets, giving a total of 120 out-
lets per country in Ghana, Nigeria, and Tanzania, and
119 outlets per country in Kenya and Uganda. Of the
598 outlets included in this study, 434 (72.6%) were
urban and 164 (27.4%) were rural.
Data collection
Qualitative interviews were conducted by telephone with
ten national (two per country) and five international mal-
aria experts. The purpose of these interviews was to iden-
tify current trends and challenges in malaria control,
AMFm effectiveness, and ACT access in the study coun-
tries. The results of these interviews were used to develop
two questionnaires: 1) A quantitative questionnaire that
gathered information on stock and sales for AMFm and
non-AMFm versions of 10 QAACT products, top-selling
anti-malarial and ACT products, major suppliers, factors
influencing anti-malarial stock and recommendation deci-
sions, rapid diagnostic testing, and perceptions around
ACT purchase and use (Outlet Survey tool). Data were
also collected on the licensure status of each outlet. Coun-
try regulations often stipulate that medication outlets
must obtain and periodically renew a license for the im-
portation, sale, dispensing, preparation, and compounding
of both over the counter (OTC) drugs and prescription
only medicines (POM). Local interviewers, who were
trained in proper interview and data collection methodolo-
gies, administered the structured questionnaire to either
the outlet manager or the most senior employee respon-
sible for drug sales present at the time of the outlet visit. 2)An open-ended, semi-structured qualitative questionnaire
that was used to assess the availability, use, and patient per-
ceptions of both ACT overall and AMFm products (Quali-
tative Survey). This questionnaire also examined differences
between urban and rural areas in regard to malaria treat-
ment perceptions and practices as well as ACT availability
and use. For each country, a representative from the local
study team completed one questionnaire.Data analysis
Data from the Outlet Survey tool were analyzed using
SAS/STAT (SAS System 9.1, SAS Institute, Cary, NC,
USA). The size of urban and rural outlets for each country
was estimated using the total tablets sold in the past week
for the top three selling ACT products. Overall stock man-
agement was assessed by determining the proportion of
QAACT products for which there had been at least one
stock-out occurrence in the previous three months, with-
out drawing a distinction between AMFm and non-AMFm
versions. Within-country results from urban and rural out-
lets were compared using chi-squared tests for independ-
ence. The mean number of stock-out days across all forms
of QAACT assessed was also calculated. Within-country
differences between urban and rural outlets were deter-
mined using appropriate t-tests.
The mean price of a full adult course of treatment for
AMFm products was determined for both rural and urban
areas in each country. This analysis was performed both
pooled (across all brands) and by brand. Additionally, the
mean price of a full adult course of the top-selling ACT
product, which included both QAACT and non-QAACT,
was calculated. Within-country differences for urban
and rural areas were determined for each mean price
using appropriate t-tests. Results from the Qualitative Sur-
vey were analyzed for themes using HyperRESEARCH
(HyperRESEARCH 3.0, ResearchWare, Randolph, MA).Results
Outlet characteristics
Outlet characteristics are summarized in Table 1. Results
are stratified by outlet location, either urban or rural. In
urban Ghana, Kenya, Tanzania, and Uganda, the majority
of the outlets surveyed were pharmacies or private clinics
(87.0%, 98.6%, 92.7%, and 89.9% respectively). In Nigeria,
only 13.4% of outlets were pharmacies or private clinics.
With the exception of Kenya and Uganda, the majority of
rural outlets surveyed were neither pharmacies nor private
clinics but instead smaller drug shops or patent medicine
stores. Patent medicine stores are licensed for the sale and
distribution of OTC drugs only. In Uganda, 41.0% of rural
outlets indicated that a pharmacy was their first line sup-
plier, compared with only 8.1% of urban outlets. Similar
trends were seen in Tanzania (see Additional file 1).
Table 1 Characteristics of urban and rural outlets selected in Ghana, Kenya, Nigeria, Tanzania, and Uganda





















Outlet type, n (%)
Pharmacy 77 (77.0) - 76 (98.6) 40 (95.0) 8 (9.7) 2 (5.3) 81 (84.4) 2 (8.3) 31 (39.3) 2 (5.0)
Drug shop 13 (13.0) 20 (100.0) - - 11 (13.4) 2 (5.3) 3 (3.1) 8 (33.3) 5 (6.3) 18 (45.0)
Private clinic/Health facility 10 (10.0) - - 2 (5.0) 3 (3.7) 1 (2.6) 8 (8.3) 4 (16.7) 40 (50.6) 20 (50.0)
Patent medicine store - - - - 54 (65.9) 32 (84.2) - - - -
Other - - 1 (1.4) - 6 (7.3) 1 (2.6) 4 (4.2) 10 (41.7) 3 (3.8) -
Outlet size, Median (Range)
Total tablets sold in the past week





















Licensed (%) 100.0 100.0 97.2 85.0 59.8 39.5 100.0 100.0 100.0 100.0
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forms of ACT sold in the week prior to the study was used
as a proxy for outlet size. As shown in Table 1, outlets sur-
veyed in Ghana were smaller than outlets surveyed in the
other four countries, especially in rural areas. Data were
also gathered on the license status of each outlet, showing
that fewer outlets surveyed in Nigeria (59.8% of urban and
39.5% of rural outlets) were licensed compared with out-
lets in the other four countries (100% for rural and urban
outlets in Ghana, Tanzania, and Uganda; 97.2% and 85.0%
of urban and rural outlets, respectively, in Kenya).
ACT affordability
The AMFm is designed to reduce the final purchase price
of QAACT. To examine price trends across products, a
pooled price analysis was performed that included 1,343
prices for AMFm products and 239 prices for correspond-
ing non-AMFm products. This analysis showed that the
mean price of a full adult course of treatment varies widely
between countries. The highest mean price was seen in
urban Uganda (US$2.42) and the lowest in rural Kenya














































*Prices given for the AMFm version of each product.
**Not an AMFm product.variation was also observed within some countries be-
tween rural and urban outlets. In Nigeria, the mean price
of AMFm products in rural areas was significantly higher
than the mean price in urban areas (US$1.24 vs. US$0.98,
p < 0.0001); this finding held true for the top-selling ACT
product (US$1.40 vs. US$1.00, p = 0.0007). In Uganda, the
opposite pattern was seen, where both the AMFm mean
price and the top-selling ACT mean price were signifi-
cantly higher in urban outlets than rural outlets (US$2.42
vs. US$1.85, p = 0.0065 for AMFm and US$2.40 vs. US
$1.78, p = 0.0053 for top-selling ACT). Similarly, in Ghana
the top-selling ACT product in urban outlets was signifi-
cantly more expensive than the top-selling product in
rural outlets (US$2.47 vs. US$0.88, p < 0.0001). However,
unlike other countries and areas, the top-selling ACT
product in Ghana was not also a product within the
AMFm QAACT list.
In this study, the mean price of AMFm products
exceeded the SRP in each country in all outlets except those
in rural Ghana. The mean price of the top-selling ACT also
exceeded country-specific SRPs for all outlets other than
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curred in Uganda, where the mean prices of AMFm and
top-selling ACT products in rural (US$1.85 and US$1.78)
and urban (US$2.42 and US$2.40) areas were approxi-
mately four to six times the SRP (US$0.42), respectively.
Despite final purchase prices that exceed SRPs, the
10 AMFm QAACT medications included in this ana-
lysis remain less expensive than non-AMFm versions
of identical drugs. The mean price of a full adult
course of AMFm Coartem (artemether-lumefantrine,
Novartis, Switzerland), the most widely available
QAACT of the 10 medications included in this ana-
lysis, ranged in urban outlets from US$0.82 (SD =
0.13) to US$2.39 (SD = 1.10). In contrast, the price of
non-AMFm Coartem in these outlets ranged from US
$6.12 (SD = 5.78) to US$9.32 (SD = 4.79). Results were
similar in rural outlets, with prices ranging from US
$0.69 (SD = 0.20) to US$2.06 (SD = 0.67) for AMFm
Coartem and US$3.51 (SD = 3.82) to US$9.37 (SD =
6.50) for non-AMFm Coartem. Prices for Lumartem
(artemether-lumefantrine, Cipla, India), with the
second-highest availability in both urban and rural
outlets, showed a similar price discrepancy. Mean
AMFm prices in all outlets varied from US$0.82 (SD
= 0.14) to US$2.28 (SD = 1.09) and non-AMFm prices
from US$0.63 (SD = 0) to US$6.72 (SD = 3.43). Over-
all, full-price QAACT was found to be up to eight
times more expensive than those subsidized through
the AMFm.
Although AMFm ACT has lower purchase prices
compared with their non-AMFm counterparts, quali-
tative findings indicate that affluent customers may
prefer to purchase the more expensive version of an
ACT due to perceptions that a less expensive drug is
also less effective. Based on data from the Qualitative
Survey, in three (Ghana, Nigeria, and Tanzania) of
the five study countries there is a shared perception
that AMFm-subsidized artemether-lumefantrine is less
effective than the unsubsidized version of the same
brand. The drastic difference in price between AMFm
subsidized and unsubsidized artemether-lumefantrine
may lead some individuals to believe that a reduction
in price is inherently coupled with a reduction in
quality. In Ghana, where unsubsidized ACT has been
on the market for a long period of time, those who
can afford the non-AMFm version of the brand often
purchase it because of the perception that the non-
AMFm version is both safer and more effective. Simi-
lar opinions were found in Nigeria and Tanzania.
Additionally, data from the Qualitative Survey re-
vealed that consumers strongly prefer fewer tablets
per dose, a factor which is taken into account when
selecting and adhering to an anti-malarial treatment
course.ACT availability
Outlets were surveyed for the availability of anti-malarial
medications, specifically those included on the list of
QAACT with both an AMFm and non-AMFm version
(Arsuamoon, Artefan, Artemef, artemether-lumefantrine,
artesunate-amodiaquine, Coartem, CoFalcinum, Combu-
sinate, Falcimon Kit, and Lumartem). In urban areas, the
proportion of outlets that had at least one AMFm
QAACT in stock at the time of visit ranged from 75.3%
in Kenya to 96.3% in Nigeria. In rural areas this figure
varied from 64.3% in Kenya to 95% in Ghana.
At each outlet, survey respondents were asked to indi-
cate if one or more of these forms of QAACT, deter-
mined to be normally in stock, had been out of stock in
the previous three months (Table 3). This analysis did
not distinguish between AMFm and non-AMFm QAACT.
In Ghana and Kenya, there was a significantly higher per-
centage of stock-out occurrences in rural areas compared
with urban areas (26.8% vs. 54.6%, p = 0.0013 in Ghana
and 78.4% vs. 87.0%, p = 0.0237 in Kenya). The mean
duration of stock-out across all products varied among
countries, with the longest time occurring in rural Kenya,
48.0 days (Standard Deviation [SD] = 23.1), and the
shortest in rural Ghana, 13.3 days (SD = 7.9). While the
durations of stock-outs differed between countries, they
were consistent between urban and rural outlets in each
country, with the exception of Ghana. In Ghana, stock-
out duration was significantly shorter in rural areas than
urban areas (p = 0.0120). Outlets in Nigeria were not in-
cluded in this analysis due to data collection assumptions
for this stock variable that differed from the other four
study countries.
A pooled analysis of all countries was undertaken to
identify the extent to which factors such as government
and drug company recommendations (including market-
ing), medication price, and physician prescription patterns
impact anti-malarial stock decisions. In this analysis, gov-
ernment recommendation was the most significant factor
influencing anti-malarial stock choices, cited by 41.5% and
31.9% of urban and rural outlets, respectively (Figure 1).
The frequency with which specific anti-malarials are pre-
scribed also plays a role, especially in Kenya and Nigeria.
In Kenya and Uganda, final patient price impacts stock
decisions. However, drug manufacturer recommendations
had little to no effect on the choice of anti-malarials
stocked in any country.
Crowd-out of monotherapies
A key objective of the AMFm programme is to “crowd
out” artemisinin monotherapies and other substandard
therapies. In order to evaluate the success of this aspect of
the programme, outlets were surveyed to determine their
three top-selling anti-malarial drugs (Table 4). The three
top-selling anti-malarials reported for both urban and
Table 3 Stock management of QAACT in urban and rural outlets*


















QAACT with at least one
stock-out occurrence
in the last 3 months (%)
26.8 54.6 0.0013 78.4 87.0 0.0237 20.6 20.4 0.9781 31.7 33.8 0.7469






















*Data not available for Nigeria.
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rural Uganda and urban Nigeria, combination therapies.
In rural Uganda, quinine was reported as the second top-
selling anti-malarial drug. In urban Nigeria, artesunate
monotherapy was listed as the second top-selling anti-
malarial. When outlet managers in each country were
asked which anti-malarial they would recommend for a
case of uncomplicated malaria in either adults or children,
there were instances of monotherapy recommendations in
all study countries except Kenya.
Discussion
The results of this study highlight the important position
held by QAACT, specifically AMFm QAACT, within the
private sector. AMFm-subsidized QAACT products are
less expensive than their non-AMFm counterparts.
Results from this study are consistent with a recent
price survey for AMFm and non-AMFm artemether-
lumefantrine in six African countries [14]. However, the
current study shows that in countries where AMFm
drugs may be perceived as less effective, wealthier
patients will pay the additional cost for non-AMFmFigure 1 Factors that affect anti-malarial stock decisions: pooled analmedications. Further research will be needed to explore
the scale of this perception and behavior. Mitigating the
negative perceptions of subsidized drugs will also be
important for increasing use of QAACT in the WHO
Africa region. Potential mitigation activities include
social marketing and education focused on the message
that lower prices are not necessarily synonymous with
lower quality. In addition to consumer perceptions of
the AMFm, qualitative interviews revealed that con-
sumers strongly consider the number of tablets per dose
when selecting an ACT. Consequently, reducing the
number of tablets in each dose will be critical for in-
creasing the use of QAACT.
The AMFm has resulted in a lower final purchase price
for a number of ACT products. Despite this success, the
price of AMFm anti-malarials reported in this study ex-
ceeds the SRPs in all outlets other than those in rural
Ghana. Additional evaluation of factors driving stocking
decisions among outlets and purchasing decisions among
consumers will be important for the achievement of prices
closer to SRPs. Given that price remains a factor in the
type of anti-malarial recommended in some areas, furtherysis, urban (n = 412) and rural (n = 158).
Table 4 Three top-selling anti-malarial products by volume for urban and rural outlets



















Top-selling Coartem Lumartem Coartem Coartem Coartem Coartem Coartem Orodar Coartem Lumartem
Second
top-selling










Lumartem Alaxin Alaxin Artemether-
Lumefantrine (Generic)
Arsuamoon Arsuamoon Metakelfin Coartem Lonart Coartem
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ing crowd-out of artemisinin monotherapies and sub-
standard anti-malarial regimens. Additionally, given that
government recommendation was the most significant
factor in stocking decisions, it is critical that governments
remove artemisinin monotherapies and substandard anti-
malarial treatments from national and institutional treat-
ment guidelines and discontinue the regulatory approvals
of these drugs.
Findings from this study also emphasize that although
there are within- and between- country differences in
AMFm QAACT availability, overall market penetration
of one or more AMFm QAACT products is high, even
in rural areas. This finding is in contrast to other survey
data gathered between 2009 and 2010, and suggests that
QAACT availability in the private sector may be improv-
ing over time [10].
This study also highlights key differences between the
types of outlets that sell anti-malarials in urban and rural
areas, which has implications for procurement and
supply chain management of anti-malarial stocks. In
Uganda and Tanzania, rural outlets, in comparison with
urban outlets, reported that they more frequently pur-
chase anti-malarials from pharmacies. These pharmacies,
in turn, are supplied directly by drug wholesalers. While
this study did not evaluate the complete supply chain of
each outlet, this finding suggests that efforts to include
outlet types such as drug shops and patent medicine
stores in the primary distribution strategy may help to
increase access to, and affordability of, QAACTs in rural
areas. Further evaluation of anti-malarial supply chains
is needed to explain the significantly higher occurrence
of stock-outs in rural versus urban outlets in Ghana and
Kenya. Supply shortages related to procurement difficul-
ties have been shown to affect the cost of ACT in
Cambodia, another AMFm Phase 1 country [15].
Additional insight is also needed regarding the impact
of product diversion on QAACT affordability and
availability.
The continued popularity of monotherapies indicates
that more work needs to be done toward achieving the
crowd-out goal of the AMFm. For example, in rural
Uganda, 41% of outlets indicated that they consider costwhen making recommendations to customers, and in
this setting monotherapies may still be the least expen-
sive anti-malarial available. This could account for the
appearance of quinine as the second top-selling anti-
malarial in rural Uganda.
Despite this result and the finding that artesunate
monotherapy was the second top-selling anti-malarial in
urban Nigeria, the overall results of this study with re-
spect to crowd-out appear to show improvement com-
pared with previous assessments. With the exception of
rural Tanzania, the top-selling anti-malarial product in
all countries, in both urban and rural areas, was a
QAACT. In contrast, data collected in 2009 and 2010
found that the anti-malarials with the highest market
share were non-artemisinin therapies in all countries
surveyed, including Ghana, Kenya, Nigeria, Tanzania,
and Uganda [10]. Based on evidence from the current
study, a direct causal argument cannot be drawn be-
tween the introduction of the AMFm and subsequent
QAACT uptake. Still, it is likely that the AMFm acted as
a catalyst for the improved accessibility of all QAACT
products through both increased supply-side pressure
and augmented supply channels. The expansion of
country-specific awareness programmes focused on the
benefits of QAACT and the risks of substandard therap-
ies will help to ensure a more efficient and effective
crowd-out process.
Following the end of the pilot phase, it was decided
that AMFm would be discontinued and the AMFm
model integrated into routine Global Fund grants [16].
There were a number of factors leading to this decision,
including concerns about the sale of anti-malarial drugs
to febrile patients who are not P. falciparum-positive
and minimal private sector uptake for paediatric formu-
lations [17]. While efforts to increase diagnostic testing,
appropriate use of anti-malarial drugs, and uptake of
paediatric treatments are warranted, these objectives
would benefit from continued efforts to improve
QAACT availability and affordability. In the absence of
AMFm subsidies, new strategies will be needed to en-
sure continued use of QAACT.
The findings presented here support the introduction of
programmes similar to AMFm as important mechanisms
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QAACT in place of artemisinin monotherapy and other
substandard therapies. Results from this study comple-
ment a recent AMFm Phase 1 evaluation, which found
substantial increases in QAACT availability (25.8-51.9 per-
centage points) and market share (15.9-40.3 percentage
points) in Ghana, Kenya, Nigeria, Tanzania, and Uganda
coupled with a decrease in final QAACT purchase price
for each country except Uganda [18].
Limitations
A key study limitation included the fact that information
related to customer and retailer treatment choice and re-
tailer ACT recommendations was based on responses
from outlet salespeople rather than direct observation. In
some cases, outlet personnel may have provided inaccur-
ate information, either unintentionally due to incomplete
knowledge of outlet practices, or intentionally in order to
present information perceived as desirable. To address this
limitation, qualitative findings were used to supplement
and aid in the interpretation of the quantitative data.
Additionally, this assessment is limited by the absence of
data on the occurrence and duration of stock-outs in
Nigeria, which arose from differences in data collection as-
sumptions between Nigeria and the other participating
countries. Despite these limitations, this study provides
new insights regarding the impact of the AMFm on
QAACT availability, QAACT affordability, and crowd-out
of monotherapies in five Phase 1 countries.
Conclusions
Mean AMFm prices in all countries were found to exceed
SRPs, potentially hindering the broader uptake of QAACT.
Additionally, monotherapies continue to be dispensed and
used in both urban and rural outlets. Still, overall AMFm
QAACT availability was high, even with stock-out and sup-
ply chain discrepancies between urban and rural areas.
Continued efforts to improve QAACT affordability and ac-
cessibility could play a crucial role in reducing malaria mor-
tality and drug resistance in endemic countries, especially if
combined with initiatives such as increased deployment of
rapid diagnostic testing, frequent supply chain monitoring,
and retailer and customer education programmes.
Additional file
Additional file 1: “Table: Primary suppliers of anti-malarial
medication for urban and rural outlets”. Personnel at each outlet
were asked to indicate the primary supplier of anti-malarial medications.
This table indicates the number and percentage of outlets citing each
supplier type as their primary source of anti-malarials. (XLS 21 kb)
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